Our Research
In parallel, we are developing a dedicated clinical research program and are actively recruiting patients for physician-led clinical studies designed to track outcomes, refine protocols, and help advance the field of regenerative medicine. Please contact us if you are interested in participating in one of our studies.
Safety of Allogeneic Mesenchymal Stromal Cell Therapy Across Human Clinical Indications: A Systematic Review of Landmark Clinical Trials and Published Safety
Peer-Reviewed Publication: Stem Cell Research International (ISSN:2639-6866)
Authors: Dr Kirk Sanford DC, Dr Félix Porras MD, Dr Fergie Martínez, MD, MSc, Dr Hugo Ramos MD, Dr Janine Zamitiz, MD, MSc, Mr Carlos Green MSc, Mr Edward Ramsay MSc
Summary: Our research reviews the safety of allogeneic mesenchymal stromal cell therapy across multiple human clinical indications, including cardiovascular, pulmonary, musculoskeletal, autoimmune, gastrointestinal, and renal conditions. Across landmark trials and major pooled analyses, the evidence supports a favorable safety profile, with no consistent signal of frequent treatment-related serious adverse events. The most commonly reported treatment-related effect has been transient fever, while no increased risk of infection, malignancy, or treatment-related mortality has been consistently identified. These findings support the continued clinical development of allogeneic MSC therapy as a scalable and generally well-tolerated regenerative medicine platform.
For patients interested in the clinical application of this research, learn more about our stem cell therapy program.
Intravenous Mesenchymal Stromal Cells for Severe and Critical COVID-19: Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Publication: Research Square
Authors: Dr Kirk Sanford DC, Dr Felix Porras MD, Dr Fergie Martinez MD, MSc, Dr Hugo Ramos MD, Dr Janine Zamitiz MD, MSc, Mr Carlos Green MSc, Mr Edward Ramsay MSc
Summary: This study examined high-quality clinical trials evaluating intravenous mesenchymal stromal cell therapy in adults with severe and critical COVID-19. By reviewing randomized, placebo-controlled studies, the analysis assessed short-term outcomes related to inflammation and clinical severity. The findings identified consistent reductions in key inflammatory markers and suggested a favorable trend in short-term outcomes, supporting continued investigation of MSC-based immunomodulatory approaches in critical illness.
For patients interested in the clinical application of this research, learn more about our stem cell therapy program.
Allogeneic Umbilical Cord Mesenchymal Stromal Cells for Knee Osteoarthritis: Systematic Review and Meta-Analysis of Controlled Injection Trials
Publication: Research Square
Authors: Dr Kirk Sanford DC, Dr Felix Porras MD, Dr Fergie Martinez MD, MSc, Dr Hugo Ramos MD, Dr Janine Zamitiz MD, MSc, Mr Carlos Green MSc, Mr Edward Ramsay MSc
Summary: This study reviewed controlled clinical trials evaluating intra-articular umbilical cord–derived mesenchymal stromal cell (MSC) injections for knee osteoarthritis. The analysis focused on longer-term pain outcomes and compared MSC injections with commonly used standard therapies. Across included studies, results showed a consistent direction of benefit at 12 months, supporting further clinical evaluation of MSC-based injection therapies for osteoarthritis.
For patients interested in the clinical application of this research, learn more about our stem cell therapy program.
Allogeneic Mesenchymal Stromal Cell-Based Therapies for Diabetic Foot Ulcers: Systematic Review and Meta-Analysis of Controlled Topical and Local Delivery Trials
Peer-Reviewed Publication: Journal of Surgery (ISSN:3117-3187)
Authors: Dr Kirk Sanford DC, Dr Felix Porras MD, Dr Fergie Martinez MD, MSc, Dr Hugo Ramos MD, Dr Janine Zamitiz MD, MSc, Mr Carlos Green MSc, Mr Edward Ramsay MSc
Summary: This study reviewed controlled clinical trials evaluating allogeneic mesenchymal stromal cell-based therapies for diabetic foot ulcers, delivered topically and or by local injection as an adjunct to standard wound care. Across included studies, MSC based approaches showed higher closure rates and greater wound area reduction, with no clear signal of increased serious treatment related adverse events. Effects on amputation outcomes were less certain due to limited event reporting, supporting the need for larger randomized trials with standardized protocols and consistent outcome reporting.
For patients interested in the clinical application of this research, learn more about our stem cell therapy program.